69 Prevention of rheumatoid arthritis Table 1 | Summary table of preventive interventional trials in individuals at risk of developing rheumatoid arthritis (continued) Trial name Inclusion criteria Number of patients (treatment vs placebo) Intervention Time of follow-up Primary outcome Secondary outcome Results Reference ARIAA study - Arthralgia - ACPA positivity - Subclinical inflammation (tenosynovitis, synovitis, or osteitis in MRI of the dominant hand) 98 patients (49 treatment vs 49 placebo) 125 mg weekly abatacept for 6 months - 6 months - 18 months - Proportion of patients with improvement of synovitis or osteitis with MRI of dominant hand at 6 months - Synovitis score at 12 and 18 months - Percentage of patients with new arthralgia - Pain score - MRI improvement - Swollen and tender joint - Percentage of patients with RA - DAS28 score - Decrease in at least one of MRI parameters (tenosynovitis, synovitis or osteitis) at 6 months (62% in treatment vs 31% in placebo group) - Reduced RA progression at 6 months (8.2% vs 34%) and 1 year (35% vs 57%) [59-61] Dexamethasone study - Arthralgia - 2x elevated IgM-RF and/ or ACPA levels - HLA-DR SE 83 patients (42 treatment vs 41 placebo) 100 mg of dexamethasone at baseline and 6 months - 6 months - 5 years - 50% reduction of autoantibody levels or normalization at 6 months - RA onset at 5 years (DAS28 or ACR 2010 criteria) - Reduction of ACPA (22%) and RF (16%) at 1 month - ACPA reduction at 6 months - No difference in RA onset (20% in treatment vs 21% in placebo) [47-48] 4
RkJQdWJsaXNoZXIy MTk4NDMw